Overview

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of Iodine-131 Anti-B1 Antibody followed by CHOP and to see what effects it has on patients with previously untreated mantel cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Corixa Corporation
Treatments:
Antibodies
Antibodies, Monoclonal
Cadexomer iodine
Cyclophosphamide
Doxorubicin
Immunoglobulins
Iodine
Iodine-131 anti-B1 antibody
Prednisone
Tositumomab I-131
Vincristine